Understanding Cannabis Genetics and Chemovars Selection for Improved Therapeutic Outcomes in Patients

Emily Rigby is a research scientist and passionate advocate for medicinal cannabis – promoting education, patient access, research, innovation, industry development, efficient production and regulatory reform.

Since 2016, Emily has played an integral role in developing the Australian medicinal cannabis industry, including establishing one of Australia’s first licenced medical cannabis cultivation and research facilities and releasing Australian grown cannabis medicines into local and export markets. Emily is also assisting in developing international cannabis industries.

Emily is on the Board of the Australian Medicinal Cannabis Association (AMCA) and Director at Protected Cropping Australia (PCA) – Australia’s peak industry body for hydroponic and greenhouse growers. Emily was President of the Australian Society of Horticultural Science from 2017 to 2021 and is a 2016 Nuffield Australia Farming Scholar. Emily was recognised as Australia’s 2021 ‘Woman of Weed’ in the Australian Cannabis Awards for her contribution to female leadership in the cannabis space.

Emily has a diverse range of expertise including propagation and cultivation methods, cannabis genetics, facility design, licensing & regulatory compliance, strategic planning, patient access, education, marketing and research from plant to patient.

Emily is dedicated to removing the stigma surrounding the Cannabis plant and facilitating the global cannabis industry.

Cannabis genetics is a rapidly evolving field with the potential to revolutionize the way we use cannabis for medicinal purposes

Understanding the therapeutic effects of cannabis genetics and the presence of specific cannabinoids and terpenes, is important to tailor treatment to individual patients.